| ID Source | ID |
|---|---|
| PubMed CID | 130667 |
| CHEMBL ID | 58763 |
| SCHEMBL ID | 891576 |
| MeSH ID | M0229205 |
| Synonym |
|---|
| gly-arg-gly-asp-ser-pro-lys |
| bdbm50079446 |
| n2-(1-(n-(n-(n-(n2-glycyl-l-arginyl)glycyl)-l-alpha-aspartyl)-l-seryl)-l-prolyl)-l-lysine |
| glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine |
| 111119-28-9 |
| l-lysine, n2-(1-(n-(n-(n-(n2-glycyl-l-arginyl)glycyl)-l-alpha-aspartyl)-l-seryl)-l-prolyl)- |
| gly-arg-gly-asp-ser-pro-lys, >=97% (hplc) |
| NCGC00167196-01 |
| grgdspk |
| glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine |
| CHEMBL58763 , |
| SCHEMBL891576 |
| emd 56574 |
| DTXSID20149506 |
| l-lysine,glycyl-l-arginylglycyl-l-a-aspartyl-l-seryl-l-prolyl- |
| HY-P0322 |
| A898918 |
| (s)-6-amino-2-((s)-1-((6s,12s,15s)-1-amino-6-(2-aminoacetamido)-12-(carboxymethyl)-15-(hydroxymethyl)-1-imino-7,10,13-trioxo-2,8,11,14-tetraazahexadecane)pyrrolidine-2-carboxamido)hexanoic acid |
| (2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid |
| MS-31214 |
| (s)-6-amino-2-((s)-1-((6s,12s,15s)-1-amino-6-(2-aminoacetamido)-12-(carboxymethyl)-15-(hydroxymethyl)-1-imino-7,10,13-trioxo-2,8,11,14-tetraazahexadecan-16-oyl)pyrrolidine-2-carboxamido)hexanoic acid |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 37.6858 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | IC50 (µMol) | 2.6240 | 0.0001 | 0.6323 | 10.0000 | AID217309; AID217312; AID220874; AID32980 |
| Integrin alpha-V | Homo sapiens (human) | IC50 (µMol) | 0.4733 | 0.0001 | 0.6256 | 10.0000 | AID217309; AID217312 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 (µMol) | 5.8500 | 0.0001 | 0.7309 | 10.0000 | AID220874; AID32980 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID32980 | Inhibitory activity against alpha IIb beta 3 integrin | 2001 | Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12 | Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists. |
| AID220874 | Inhibition of alpha IIb beta-3 integrin binding to fibrinogen | 1999 | Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16 | N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. |
| AID217309 | Inhibitory activity against vitronectin receptor (alpha V beta 3) | 2001 | Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12 | Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists. |
| AID233865 | Selectivity designates the quotient of affinities to integrins alpha v beta-3 and alpha IIb beta3 | 2001 | Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12 | Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists. |
| AID217312 | Inhibition of Vitronectin receptor (alpha V beta 3) binding to fibrinogen | 1999 | Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16 | N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||